J&J : Phase 3 Data Show RYBREVANT LAZCLUZE Outperforms Osimertinib In Non-small Cell Lung Cancer

(RTTNews) - Johnson & Johnson (JNJ) today announced that longer follow-up data from the landmark Phase 3 MARIPOSA study demonstrated that first-line treatment with RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) provided consistent benefits across long-term outco https://www.nasdaq.com/articles/jj-phase-3-data-show-rybrevant-lazcluze-outperforms-osimertinib-non-small-cell-lung-cancer